

# LISTE DES FINANCEMENTS ACCORDES PAR L'AFM-TELETHON EN 2025

Au titre de sa mission Guérir (hors financements accordés à Généthon, CECS-Istem, Institut de Myologie)

## POLITIQUE D'APPEL D'OFFRES

### Projets soumis à l'appel d'offres annuel

#### Commission thématique : Myologie Fondamentale

##### Aides aux jeunes chercheurs post-doctorants

<b>GUILCHER</b>	<b>Marine</b>	MONTPELLIER	FRANCE	Elucidating the Hox transcription factor Ubx-RNA binding specificity at the nucleotide resolution during muscle morphogenesis
<b>KUROSAWA</b>	<b>Tamaki</b>	PARIS	FRANCE	Regionalization of fibroblasts of muscle attachments
<b>PONTHEAUX</b>	<b>Florian</b>	BANYULS-SUR-MER	FRANCE	Smooth muscles as mechano-chemical regulators of repair processes: nature of the actin-based topological defects during jellyfish regeneration
<b>SACLIER</b>	<b>Marielle</b>	PARIS	FRANCE	Impact of Senescent Cell-Macrophage Crosstalk in Muscle Repair

##### Financements de projets

<b>BLAAUW</b>	<b>Bert</b>	PADOVA	ITALIE	Identification of muscle-specific factors involved in NMJ maintenance and their regulation by mTORC1
<b>CARNESECCHI</b>	<b>Julie</b>	MONTPELLIER	FRANCE	Illuminating the isoform-regulatory function of the Hox transcription factor Ultrabithorax during muscle development
<b>CHAHINE</b>	<b>Mohamed</b>	QUÉBEC	CANADA	Unveiling the role of a key modulator in cardiac electrophysiology and ion channel trafficking: Insights from iPSC models and knock-in mice
<b>DE ALMEIDA</b>	<b>Sergio</b>	LISBOA	PORTUGAL	Unveiling the DNA Damage Response in Skeletal Muscle Resilience and Repair
<b>DUPREZ</b>	<b>Delphine</b>	PARIS	FRANCE	Regionalisation of myogenesis
<b>ENRIQUEZ</b>	<b>Jonathan</b>	LYON	FRANCE	Spatio temporal control of muscle diversity
<b>KIM</b>	<b>Minchul</b>	ILLKIRCH	FRANCE	Translational control of myotendinous junction by Tgd4/Staufen complex
<b>LEFKIMMIATIS</b>	<b>Konstantinos</b>	PAVIA	ITALIE	The spatiotemporal map of nuclear signalling in the aging muscle
<b>MENZIES</b>	<b>Keir</b>	OTTAWA	CANADA	Examining the role and therapeutic potential of Poly-ADP-Ribosylation (PARylation) in myopathies and skeletal muscle maintenance and function
<b>NEVES</b>	<b>Joana</b>	LISBOA	PORTUGAL	The contribution of immune aging to skeletal muscle regenerative failure
<b>ROMAN</b>	<b>William</b>	CLAYTON	AUSTRALIE	Monitoring the transcriptional repair program after local muscle damage
<b>ROMANELLO</b>	<b>Vanina</b>	PADOVA	ITALIE	The in vivo role of peroxisomes in the control of muscle function
<b>ROMANELLO</b>	<b>Vanina</b>	PADOVA	ITALIE	Study of peroxisomes as a metabolic link to muscle regeneration
<b>SAURIN</b>	<b>Andrew</b>	MARSEILLE	FRANCE	Hox control of Drosophila adult myogenesis
<b>SINIGAGLIA</b>	<b>Chiara</b>	BANYULS-SUR-MER	FRANCE	Jellyfish smooth muscles in development, tissue repair and regeneration

#### Commission thématique : Bases Moléculaires et Physiopathologie des Dystrophies Musculaires

##### Aides aux jeunes chercheurs post-doctorants

<b>CALABRÒ</b>	<b>Sonia</b>	PADOVA	ITALIE	Investigating the role of gut microbiota in the pathogenesis of Collagen VI-related myopathies
<b>DASKALAKI</b>	<b>Ioanna</b>	LAUSANNE	SUISSE	DeLIP-PAM: Targeting sphingolipids for the treatment of Protein Aggregate Myopathies
<b>DEPREZ</b>	<b>Alyson</b>	MONTRÉAL	CANADA	Trained immunity, macrophages and muscle stem cells in dystrophic respiratory muscle
<b>FERNANDEZ SIMON</b>	<b>Esther</b>	NEWCASTLE UPON TYNE	UK	Targeting C4BPA as a therapeutic approach in muscle dystrophies
<b>TORCINARO</b>	<b>Alessio</b>	MONTEROTONDO SCALO	ITALIE	Role of miR-200c and oxidative stress in FSHD

## Financements de projets Tremplins

<b>CESCON</b>	<b>Matilde</b>	PADOVA	ITALIE	Investigating the role of gut microbiota in the pathogenesis of Collagen VI-related myopathies
<b>FERNANDEZ SIMON</b>	<b>Esther</b>	NEWCASTLE UPON TYNE	UK	Targeting C4BPA as a therapeutic approach in muscle dystrophies
<b>RUPARELIA</b>	<b>Avnika</b>	VICTORIA	AUSTRALIE	Extracellular matrix remodelling in LAMA2-related muscular dystrophy: friend or foe?
<b>SORGE</b>	<b>Matteo</b>	TURIN	ITALIE	Melusin changes the fate of ERK1/2 in Emery-Dreifuss cardiomyopathy

## Financements de projets

<b>CHARLET-BERGUERAND</b>	<b>Nicolas</b>	ILLKIRCH	FRANCE	Decipher the mechanisms underlying muscle weakness in Myotonic Dystrophy
<b>COPPEE</b>	<b>Frédérique</b>	MONS	BELGIQUE	Characterization of DUX4 and DUX4c major protein partners to identify new therapeutic targets for facioapulohumeral muscular dystrophy (FSHD)
<b>DE GREEF</b>	<b>Jessica</b>	LEIDEN	PAYS-BAS	Muscle-on-chip: a novel approach for studying DUX4-induced events in FSHD
<b>DÍAZ-MANERA</b>	<b>Jordi</b>	NEWCASTLE	UK	MATRIX: Understanding the role of extracellular matrix in the process of muscle degeneration in muscular dystrophies
<b>ESCANDE-BEILLARD</b>	<b>Nathalie</b>	ISTANBUL	TURQUIE	Novel Muscular Dystrophy caused by SNUPN Mutations: From Innovative modeling to therapeutic insights
<b>JASMIN</b>	<b>Bernard</b>	OTTAWA	CANADA	Therapeutic potential of AMPK in Myotonic Dystrophy type 1 (DM1)
<b>PEYRON</b>	<b>Christelle</b>	BRON	FRANCE	Sleep alteration in a mouse model of DM1
<b>RAVEL-CHAPUIS</b>	<b>Aymeric</b>	OTTAWA	CANADA	Characterization of the DM1 myosecretome and its multisystemic impact
<b>SACCONE</b>	<b>Valentina</b>	ROME	ITALIE	The RNA-Binding Protein hnRNPAB1 is a key protein controlling microRNA sorting into Fibro-Adipogenic Progenitor derived Extracellular Vesicles, crucial for muscle regeneration in Duchenne Muscular Dystrophy
<b>TEDESCO</b>	<b>Francesco Saverio</b>	LONDON	UK	Studying the impact of nuclear shape abnormalities in laminopathies using advanced in vitro models
<b>THORSTEINSDOTTIR</b>	<b>Solveig</b>	LISBON	PORTUGAL	Identifying and targeting molecular pathways involved in LAMA2-CMD onset
<b>VAN PUTTEN</b>	<b>Maaïke</b>	LEIDEN	PAYS-BAS	Characterization of four humanized mouse models for Duchenne muscular dystrophy

## Commission thématique : Bases Moléculaires & Physiopathologie des Maladies Neuromusculaires autres que les Dystrophies Musculaires

### Aides aux jeunes chercheurs post-doctorants

<b>SILVA-ROJAS</b>	<b>Roberto</b>	MADRID	ESPAGNE	MetaTitin: The sleeping giant of skeletal muscle
--------------------	----------------	--------	---------	--

## Financements de projets

<b>BRIS</b>	<b>Céline</b>	ANGERS	FRANCE	Urine-derived cells for non-invasive diagnosis of mitochondrial diseases
<b>CASTETS</b>	<b>Perrine</b>	GENÈVE	SUISSE	Deciphering the multiple pathophysiological facets of the chaperone VMA21
<b>COPIK</b>	<b>Alenka</b>	MONTPELLIER	FRANCE	Establishment of molecular mechanisms leading to protein aggregation and amyloid formation in distal myopathy patients using multidisciplinary approaches including genetic screening, bioinformatics and biochemical and structural analysis
<b>DUVEZIN-CAUBET</b>	<b>Stéphane</b>	BORDEAUX	FRANCE	Characterization of the molecular role of TMEM70 in the biogenesis of mitochondrial F1Fo-ATP synthase
<b>FERNANDEZ-VIZARRA</b>	<b>Erika</b>	HUESCA	ESPAGNE	Tissue-specificity of complex III dysfunction in mitochondrial encephalomyopathies
<b>GARAUDE</b>	<b>Johan</b>	BORDEAUX	FRANCE	Revealing macrophages contribution to mitochondrial myopathy
<b>KÜHL</b>	<b>Inge</b>	GIF-SUR-YVETTE	FRANCE	Investigating the role of an uncharacterized mitochondrial RNA Polymerase-associated Factor: towards a finer understanding of mammalian OXPHOS biogenesis
<b>METODIEV</b>	<b>Metodi</b>	PARIS	FRANCE	Molecular basis of impaired OXPHOS biogenesis caused by deficient protein maturation in mitochondria
<b>MITRANI-ROSENBAUM</b>	<b>Stella</b>	JERUSALEM	ISRAËL	Novel insights in GNE Myopathy mechanism of action
<b>STEFFANN</b>	<b>Julie</b>	PARIS	FRANCE	MITOCARE: Mitochondrial replacement therapy (MRT) against mitochondrial DNA (mtDNA) disorders: are we far from its clinical application?
<b>VANDROMME</b>	<b>Marie</b>	TOULOUSE	FRANCE	Epigenetic contribution in the etiology of Myotubular Myopathy

## Commission thématique : Système Nerveux et Jonction Neuromusculaire

### Aides aux jeunes chercheurs post-doctorants

<b>BASTO</b>	<b>Clara</b>	VILLEJUIF	FRANCE	GAA:TTC repeat expansions and neuromuscular degeneration
<b>GUERRA</b>	<b>Marika</b>	ROME	ITALIE	Investigating the functional role of SMN circRNAs in SMA motor neurons differentiation and viability
<b>MILIOTO</b>	<b>Carmelo</b>	PADOVA	ITALIE	Investigating spinal motor neurons vulnerability in C9orf72 DPR knock-in mouse models
<b>MORRONI</b>	<b>Jacopo</b>	ROME	ITALIE	Unveiling the phenotype of autoreactive B cells in MuSK-associated myasthenia gravis through combined single cell technologies
<b>NABAVIZADEH</b>	<b>Nasrinsadat</b>	ISTANBUL	TURQUIE	Deciphering the function of a novel gene in an ALS-like syndrome
<b>RUSSO</b>	<b>Loris</b>	PADOVA	ITALIE	Targeting Beclin 1-Regulated pathways to counteract peripheral demyelination

### Financements de projets Tremplins

<b>ESTEVEES</b>	<b>Filipa</b>	FARO	PORTUGAL	The role of RNA-binding proteins in Spinocerebellar ataxia type 3 (SCA3): from pathogenesis to disease-modifying therapy
<b>MATOS RODRIGUES</b>	<b>Gabriel</b>	VILLEJUIF	FRANCE	Pathogenic expanded GAA:TTC repeats and neuromuscular degeneration: mechanisms of gene silencing and repeat expansions
<b>MORANT</b>	<b>Laura</b>	ANTWERP	BELGIQUE	Exploring the role of YARS1 in peripheral neuropathy: reconstructing its interaction with actin
<b>MORRONI</b>	<b>Jacopo</b>	ROME	ITALIE	Unveiling the phenotype of autoreactive B cells in MuSK-associated myasthenia gravis through combined single cell technologies
<b>ROMEO GUITART</b>	<b>David</b>	PARIS	FRANCE	Bone-Primary Cilia Signaling in the progression of motoneuron disease

### Financements de projets

<b>BOWERMAN</b>	<b>Melissa</b>	STAFFORDSHIRE	UK	Defining the role of brown adipose tissue in metabolic defects in SMA
<b>CHEVROLIER</b>	<b>Arnaud</b>	ANGERS	FRANCE	Unexplored aspects of proteostasis in MFN2-related CMT2A2
<b>LEE</b>	<b>Young Il (Matt)</b>	GAINESVILLE	USA	Contribution of impaired and maladaptive motor innervation of muscle fibers to progressive pathology of muscular dystrophy
<b>MONANI</b>	<b>Umrao R.</b>	NEW YORK	USA	How does a novel spinal muscular atrophy modifier suppress motor neuron disease?
<b>ORTEGA CANO</b>	<b>Juan Alberto</b>	L'HOSPITALET DE LLOBREGAT	ESPAGNE	Defining the contribution of ALS-associated alterations in motor neuron microenvironment to disease pathogenesis
<b>PENNUTO</b>	<b>Maria</b>	PADOVA	ITALIE	Development of a therapeutic strategy to suppress LSD1 and PRMT6-mediated toxic gain of function in SBMA
<b>POLETTI</b>	<b>Angelo</b>	MILAN	ITALIE	Pathogenic mechanisms of HSPB8 mutations in neuromuscular diseases: the role of the ribosomal and protein quality control system and the integrated stress response
<b>RINALDO</b>	<b>Cinzia</b>	ROME	ITALIE	Spastin elevating approaches to counteract Hereditary Spastic Paraplegia
<b>ROJO</b>	<b>Manuel</b>	BORDEAUX	FRANCE	Cellular assays to establish the consequences and infer the pathogenicity of MFN2 variants
<b>TARESTE</b>	<b>David</b>	PARIS	FRANCE	Core Molecular Mechanisms and Lipid Determinants of Mitofusin-mediated Mitochondrial Fusion

## Commission thématique : Cellules Souches

### Aides aux jeunes chercheurs post-doctorants

<b>GRISSETI</b>	<b>Elena</b>	TOULOUSE	FRANCE	Characterizing the features of mobilizable adipose stromal cells participating to muscle regeneration and their alterations during aging
<b>LY</b>	<b>Ha My</b>	OTTAWA	CANADA	The role of PINK1/PARKIN mediated the mitophagy in the regulation of muscle stem cell fate choices and muscle regeneration
<b>POITOU MOUCAUD</b>	<b>Blandine</b>	MONTRÉAL	CANADA	Optogenetics and muscle atrophy: delivery of optogenetic contractile properties to skeletal muscle by MuSCs

### Financements de projets Tremplins

<b>ORTS-DEL IMMAGINE</b>	<b>Adeline</b>	PARIS	FRANCE	Warburg Micro syndrome : autophagy's role in the pathophysiological development of cortical neurons
<b>VAN LENT</b>	<b>Jonas</b>	BELLINZONA	SUISSE	Exploring human neuromuscular reflex arcs in vitro using assembloid models

## Financements de projets

<b>BIRCHMEIER</b>	<b>Carmen</b>	BERLIN	ALLEMAGNE	Oscillatory gene expression in human iPSC-derived myogenic cells
<b>BURELLE</b>	<b>Yan</b>	OTTAWA	CANADA	Targeting mitochondrial quality control in stem cells to promote muscle repair
<b>CARETTI</b>	<b>Giuseppina</b>	MILAN	ITALIE	BET inhibitors rewire lipid metabolism in mdx satellite cells
<b>FERRETTI</b>	<b>Patrizia</b>	LONDON	UK	Metabolic defects as potential therapeutic targets for Duchenne Muscular Dystrophy neural pathology
<b>FUKADA</b>	<b>So-Ichiro</b>	OSAKA	JAPON	Identification of extrinsic factors involved in MuSC self-renewal in physiological and pathological environments
<b>GUARDIOLA</b>	<b>Ombretta</b>	NAPOLI	ITALIE	Exploring the complexity of chemokine/chemokine receptor dynamics in muscle stem cell population: insights into CXCR2 signalling and heterogeneity
<b>KHACHO</b>	<b>Mireille</b>	OTTAWA	CANADA	Targeting mitochondrial dynamics and metabolites in muscle stem cells as a therapy for Duchenne Muscular Dystrophy
<b>ZAMMIT</b>	<b>Peter</b>	LONDON	UK	Induced Pluripotent Stem Cell models to decipher pathomechanisms in FSHD

## Commission thématique : Thérapie Génique et/ou Cellulaire des Maladies Rares

### Financements de projets Tremplins

<b>BARGIELA</b>	<b>Ariadna</b>	BURJASSOT	ESPAGNE	Advanced Therapeutic Strategies Using Antisense Oligonucleotides Targeting MS12 for the Treatment of Myotonic Dystrophies
-----------------	----------------	-----------	---------	---

### Financements de projets

<b>ARRIBAT</b>	<b>Yoa</b>	MONTPELLIER	FRANCE	Development of the first system of organelle optimisation and transplantation to treat mitochondrial diseases
<b>BELENGUER</b>	<b>Pascale</b>	TOULOUSE	FRANCE	Proof of principle of an original gene therapy for a rare hereditary mitochondrial-related optic atrophy
<b>BORTOLUSSI</b>	<b>Giulia</b>	TRIESTE	ITALIE	Improving Targeted Genome Integration in the Adult Liver to Treat Rare Genetic Metabolic Diseases
<b>BRUNETTI-PIERRI</b>	<b>Nicola</b>	POZZUOLI	ITALIE	Gene therapy for Wolman disease
<b>CHEMELLO</b>	<b>Francesco</b>	BOLOGNA	ITALIE	Editing Detection In Transcriptome: Deciphering the Gene Editing Outcomes in DMD Using snRNA-seq and Spatial Transcriptomics
<b>EL AMRAOUI</b>	<b>Aziz</b>	PARIS	FRANCE	Humanized mice to expedite effective translation of reliable inner ear gene therapies
<b>GRANDIS</b>	<b>Marina</b>	GENOVA	ITALIE	Development of Allele-Specific Gene-Silencing siRNAs for MPZ-D61N in CMT1B Neuropathy
<b>GRITTI</b>	<b>Angela</b>	MILAN	ITALIE	Hematopoietic Stem Cell Gene Therapy (HSC GT) for GM2 Gangliosidosis: Advancing Therapeutic Efficacy and Translational Potential
<b>HOVNIANIAN</b>	<b>Alain</b>	PARIS	FRANCE	Base editing-mediated correction of recurrent mutations in COL7A1 to treat RDEB
<b>LATTANZI</b>	<b>Wanda</b>	ROME	ITALIE	Nano-ink based Antisense oligonucleotide delivery for Ultra-personalized treatment of Syndromic craniosynostoses
<b>MINCZUK</b>	<b>Michal</b>	CAMBRIDGE	UK	Mitochondrial Genome Base Editing for Advancing Therapies of Neuromuscular Diseases
<b>MOINE</b>	<b>Hervé</b>	ILLKIRCH	FRANCE	AAV-DGKK gene therapy for the treatment of Fragile X syndrome
<b>MONANI</b>	<b>Umrao R.</b>	NEW YORK	USA	Modulating SLC2A1 activity with a novel lncRNA to treat infantile-onset Glucose Transporter-1 deficiency syndrome
<b>MORLANDO</b>	<b>Mariangela</b>	ROME	ITALIE	Targeting IRF2BPL non-sense mutations with suppressor tRNAs
<b>MURO</b>	<b>Andrés F.</b>	TRIESTE	ITALIE	Combination of mRNA-LNP and gene targeting approaches as a potential cure for early onset severe Ornithine transcarbamylase deficiency
<b>ROYBON</b>	<b>Laurent</b>	GRAND RAPIDS	USA	Targeting STING to prevent astrocyte toxicity to motor neurons in ALS
<b>SCHIFF</b>	<b>Manuel</b>	PARIS	FRANCE	Optimization of AAV gene therapy in MSUD
<b>SMEETS</b>	<b>Hubert J. M.</b>	MAASTRICHT	PAYS-BAS	Assess efficacy of intra-arterial autologous myogenic stem cell therapy for m.3243A>G mutation carriers
<b>SORRENTINO</b>	<b>Vincenzo</b>	SIENA	ITALIE	Investigating the potential of miR-486 overexpression to enhance skeletal muscle function in mouse models of recessive RYR1-related myopathies
<b>TASFAOUT</b>	<b>Hichem</b>	SEATTLE	USA	Expression of large dystrophins using AAV and split inteins
<b>TREPICCIONE</b>	<b>Francesco</b>	NAPLES	ITALIE	Treating Fanconi-Bickel Syndrome with an AAV-KP1-pSgt2-Glut2 gene therapy approach

## Commission thématique : Thérapie Pharmacologique et Recherche Translationnelle sur les Maladies NeuroMusculaires

### Aides aux jeunes chercheurs post-doctorants

<b>BARQUISSAU</b>	<b>Valentin</b>	TOULOUSE	FRANCE	Role of phosphoinositides in the pathophysiology of X-linked centronuclear myopathy (XLCNM)
<b>BOULINGUIEZ</b>	<b>Alexis</b>	EGHAM	UK	Pharmacological approaches to improve folding of microdystrophin in Duchenne muscular dystrophy
<b>FABBRIZIO</b>	<b>Paola</b>	MILAN	ITALIE	Modulating the P2X7 axis in Spinal and Bulbar Muscular Atrophy muscle cell populations as an innovative approach to promote myogenesis
<b>VAN DE WAL</b>	<b>Melissa</b>	DÜSSELDORF	ALLEMAGNE	iPSC-driven repositioning of Sildenafil to treat Leigh syndrome

### Financements de projets Tremplins

<b>BELTRÀ BACH</b>	<b>Marc</b>	BARCELONA	ESPAGNE	Validation of a new Charcot-Marie-Tooth 2A model amenable for therapy search
<b>MANTUANO</b>	<b>Paola</b>	BARI	ITALIE	Investigating the role of mitochondrial translocator protein (TSPO) in Duchenne muscular dystrophy: pathophysiological and therapeutic implications

### Financements de projets

<b>BADRISING</b>	<b>Umesh</b>	LEIDEN	PAYS-BAS	Optimism for Inclusion Body Myositis: a double-blind randomized placebo-controlled clinical trial with Sirolimus to halt disease progression
<b>CHARTRAND</b>	<b>Pascal</b>	MONTREAL	CANADA	Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in a DM1 mouse model
<b>D'ANTONIO</b>	<b>Maurizio</b>	MILAN	ITALIE	Targeting the P-eIF2alpha/PPP1R15A branch of the UPR with IFB-088 as a therapeutic strategy in adult CMT1A/B mice
<b>DE PALMA</b>	<b>Clara</b>	MILAN	ITALIE	Evaluation of SRT2104 potential in skeletal and cardiac muscle recovery in a severe model of DMD
<b>DEVAUX</b>	<b>Jérôme</b>	MONTPELLIER	FRANCE	Role of ADAM Metalloproteases in autoimmune Nodopathy
<b>DUPUIS</b>	<b>Luc</b>	STRASBOURG	FRANCE	Preclinical evaluation of dual orexin receptor antagonist in amyotrophic lateral sclerosis
<b>HNIA</b>	<b>Karim</b>	TOULOUSE	FRANCE	Development and validation of PI3KC2b inhibitors for therapeutic application in XLCNM
<b>MALERBA</b>	<b>Alberto</b>	EGHAM	UK	Improving protein folding to enhance microdystrophin expression in Duchenne muscular dystrophy
<b>NARDO</b>	<b>Giovanni</b>	MILAN	ITALIE	Allosteric agonism of purinergic P2X7 receptor as a pharmacological approach to enhance skeletal muscle regeneration in Spinal Bulbar Muscular Atrophy
<b>NICOLAOU</b>	<b>Paschalis</b>	NICOSIA	CHYPRE	Charcot-Marie-Tooth microRNA biomarkers discovery
<b>SANDONÀ</b>	<b>Dorianna</b>	PADOVA	ITALIE	Target validation approach to unveil the mechanism of action of C17 in sarcoglycanopathies

## Commission thématique : Recherche Médicale

### Aides aux jeunes chercheurs post-doctorants

<b>ANDRADE</b>	<b>Ricardo</b>	NANTES	FRANCE	Innovative Multiparametric UltraSound biomarkers for muscular dystrophies: towards a comprehensive monitoring of musCLE degeneration and responses to therapy
<b>FORTIN</b>	<b>Julie</b>	SAGUENAY	CANADA	Evaluating the Effectiveness of Light Therapy Interventions to Enhance Sleep Quality and Social Participation in Myotonic Dystrophy Type 1

### Financements de projets

<b>ANGEARD</b>	<b>Nathalie</b>	BOULOGNE-BILLAN COURT	FRANCE	Towards a better understanding of the neurocognitive profile of adults with the childhood phenotype of myotonic dystrophy type 1: an interdisciplinary approach
<b>CLAEYS</b>	<b>Kristl</b>	LEUVEN	BELGIQUE	Multimodal approach to study bone and muscle involvement in Facio-Scapulo-Humeral muscular dystrophy (FSHD)
<b>CORTESE</b>	<b>Andrea</b>	LONDON	UK	Long-read Sequencing In Undiagnosed Neuromuscular Diseases
<b>GAGNON</b>	<b>Cynthia</b>	JONQUIERE	CANADA	Selecting and validating a patient-reported outcome measure for the assessment of dysphagia in DM1
<b>SERGEANT</b>	<b>Nicolas</b>	LILLE	FRANCE	Assessment of central nervous system neurodegeneration and impact of type II diabetes in Myotonic Dystrophy type I

## Appel d'offres Doctorants

<b>BOURGETON</b>	<b>Tiffany</b>	NANTES	FRANCE	Effect of Enzyme replacement therapy (ERT) on skeletal muscle pathophysiology in Pompe disease : specific focus on satellite cells and autophagy
<b>DAY</b>	<b>Lucie</b>	PARIS	FRANCE	Role of ADAR1 and RNA editing in peripheral myelin maintenance
<b>GISBERT</b>	<b>Vincent</b>	MONTPELLIER	FRANCE	Organelle alterations converge on neurodegeneration and lack of regeneration in hereditary spastic paraplegia
<b>HAUTOBOIS</b>	<b>Marie</b>	PARIS	FRANCE	Base editing-mediated correction of recurrent mutations in COL7A1 to treat RDEB
<b>JAULIAC</b>	<b>Edgar</b>	PARIS	FRANCE	Role of Innervation in the Coordination and Activation of the Fast Glycolytic Program in Adult Muscle Fiber: Study of the c-MAF Transcription Factor
<b>LECLERCQ</b>	<b>Rémi</b>	PARIS	FRANCE	Unequal mitotic mitochondrial segregation as an asymmetric fate determinant in neural stem cells
<b>LEROUX</b>	<b>Emma</b>	RENNES	FRANCE	The transcriptional dynamics of muscle stem cells response to Notch signaling
<b>MACAUX</b>	<b>Gaspard</b>	PARIS	FRANCE	The crosstalk between motoneurons and myofibers
<b>ROLLAND</b>	<b>Fanny</b>	MONTPELLIER	FRANCE	Characterization of the first organelle factory for therapeutic transplantation
<b>ROUÉ</b>	<b>Clémence</b>	MONTPELLIER	FRANCE	Autoimmune Nodopathy : DEtermine the RoleS Of ADAM10/17 in Neuropathy
<b>ROUSSET</b>	<b>Célia</b>	MARSEILLE	FRANCE	Defining the unique developmental program of the trapezius muscle
<b>RUBENS</b>	<b>Paula</b>	PARIS	FRANCE	DNA Methylation Landscape of Normal, Mitochondrial Mutated, and Three-Parent Preimplantation Embryos
<b>SMITH</b>	<b>Coalesco</b>	STRASBOURG	FRANCE	Myotendinous junction development driven by transient embryonic gene expression program
<b>VAUCOURT</b>	<b>Mathilde</b>	TOULOUSE	FRANCE	Selective autophagy in X-linked centronuclear myopathy: molecular mechanisms and pathophysiological relevance
<b>YTIER</b>	<b>Charline</b>	MARSEILLE	FRANCE	Modeling, modulating, and monitoring intramuscular fibro-fatty infiltrates

## Projets soumis à l'appel d'offres thématique Médecine Mitochondriale

<b>MARTI</b>	<b>Ramon</b>	BARCELONA	ESPAGNE	Deoxynucleosides as a potential therapy for mitochondrial DNA maintenance disorders
<b>PROCACCIO</b>	<b>Vincent</b>	ANGERS	FRANCE	Therapeutic strategies targeting mitochondrial dysfunction and inflammation in mitochondrial diseases

## Partenariats institutionnels

<b>AUTHIER</b>	<b>François-Jérôme</b>	CRETEIL	FRANCE	BIGTIM: Blocking Interferon-gamma by Ruxolitinib for Treating Inclusion body Myositis - a phase IIB trial"
<b>LAUGEL</b>	<b>Vincent</b>	STRASBOURG	FRANCE	Cohorte de suivi longitudinal SMA-DNN: Dépistage néonatal de l'Amyotrophie Spinale - Projet pilote SMA-DNN France

## Partenariats associatifs

<b>IFCAH</b>		PARIS	FRANCE	Financement du projet : - Adrenocortical cells and organoids derived from human induced-pluripotent stem cells - Yasmine NEIRIJINCK
<b>RETINA France</b>		COLOMIERS	FRANCE	Financement du renouvellement des projets : - Une thérapie génique innovante pour l'amaurose congénitale de Leber liée à la RDH12 - Deniz DALKARA - Approches de thérapie oligonucléotidique antisens et de thérapie génique pour le traitement des maladies dégénératives rétiniennes en ciblant la voie glyco-gène synthase kinase 3 - Jérôme ROGER - Stratégie de restauration visuelle par approche combinée de la transplantation cellulaire et de l'optogénétique - Gaël ORIEUX
<b>SMA EUROPE</b>		CHIPPING CAMDEN	UK	12ème appel à projets international pour la recherche sur la SMA - Co-financement des projets : - Leveraging SMN role in translation to develop the next-gen of biomarkers for SMA - VIERO Gabriella - Skeletal Muscle Stem Cells as untapped therapeutic targets for SMA long-term treatment - DIDIER Nathalie - Deciphering the Molecular Landscape of Neuromuscular Development in Spinal Muscular Atrophy - GAZZOLA Morgan - Investigating Calcium-induced mitochondrial dysfunction in zebrafish and iPSC models of SMA - CIURA Sorana - Are microvascular defects relevant in Spinal Muscular Atrophy?: Characterization of the mouse model - PARSON Simon
<b>VAINCRE LA MUCOVISCIDOSE (VLM)</b>		PARIS	FRANCE	Financement des projets : - Ciblage des ARNT pour une suppression traductionnelle spécifique de mutations non-sens dans le gène CFTR - Olivier NAMY - Ciblage de l'ARNm TTP comme régulateur de la réponse inflammatoire - Magali CADARS

## Projets Ignition

<b>EVANO</b>	<b>Brendan</b>	PARIS	FRANCE	Targeted Genetic Manipulation of Muscle Stem Cells in vivo Towards New Treatment Strategies Against Muscular Dystrophies
<b>NICOLE</b>	<b>Sophie</b>	MONTPELLIER	FRANCE	Nav1.4 activators for a correction of SCN4A-related muscle weaknesses

## ACTIONS STRATEGIQUES

### Projets stratégiques

<b>AGBULUT</b>	<b>Onnik</b>	PARIS	FRANCE	DESmin-related CARdiomyopathy Therapeutic Development - DESCARTES
<b>ALLAMAND</b>	<b>Valérie</b>	PARIS	FRANCE	Physiopathology and therapeutic strategies for LAMA2-CMD
<b>AUSSEIL</b>	<b>Jérôme</b>	TOULOUSE	FRANCE	Gene therapy for Sanfilippo B syndrome
<b>BOMONT</b>	<b>Pascale</b>	LYON	FRANCE	Therapy for Giant Axonal Neuropathy
<b>DOWLING</b>	<b>James</b>	PHILADELPHIA	USA	Development of a non-viral delivery based genetic medicine platform for neuromuscular disorders
<b>DUMONCEAUX</b>	<b>Julie</b>	LONDON	UK	Myostatin: a biomarker for Facioscapulohumeral dystrophy
<b>GALY</b>	<b>Anne</b>	CORBEIL-ESSONNES	FRANCE	Sickle cell disease gene therapy program
<b>HUDA</b>	<b>Ruksana</b>	GALVESTON	USA	Developing mAb-siRNA conjugate for therapy of myasthenia gravis
<b>LAPORTE</b>	<b>Jocelyn</b>	ILLKIRCH	FRANCE	Pathophysiology and therapeutic proof-of-concepts for congenital myopathies
<b>MALFATTI</b>	<b>Edoardo</b>	CRÉTEIL	FRANCE	UPHoD - Ultrarare PYROXD1, ACTN2, and FHL1 congenital-myopathies Pharmacological treatment through HiPSC-based Drug repurposing
<b>OLIVIER-FAIVRE</b>	<b>Laurence</b>	DJON	FRANCE	PERIGENOMED-CLINICS 1: a pre-pilot to assess the feasibility and acceptability of newborn screening using panel-based genome sequencing in France
<b>POURQUIE</b>	<b>Olivier</b>	BOSTON	USA	Immuno-evasion of human satellite cells generated in vitro
<b>PROCACCIO</b>	<b>Vincent</b>	ANGERS	FRANCE	Identifying candidate drugs in mitochondrial cardiomyopathies: From Mouse to Human
<b>PROCACCIO</b>	<b>Vincent</b>	ANGERS	FRANCE	From mechanisms to therapies: Mitochondrial drug combinations to tackle multiple mitochondrial disorders
<b>REYNGOUDT</b>	<b>Harmen</b>	PARIS	FRANCE	MyoBrain-BMD: A multi-modal study including quantitative brain and muscle MRI, (neuro)psychological tests and muscle functional tests to investigate differences between Dp140+ and Dp140- Becker muscular dystrophy patients
<b>SAKER</b>	<b>Safaa</b>	EVRY	FRANCE	Efficacy, activity and safety of low-dose IL-2 (Id-IL-2) as a Treg enhancer for anti-neuroinflammatory therapy in newly diagnosed Amyotrophic Lateral Sclerosis (ALS) patients
<b>SEFERIAN</b>	<b>Andreea</b>	PARIS	FRANCE	A prospective, longitudinal, interventional natural history study of children with LAMA2 congenital muscular dystrophy
<b>SEREDA</b>	<b>Michael</b>	GÖTTINGEN	ALLEMAGNE	A multi-omic approach to the identification of novel biomarkers in early Charcot-Marie-Tooth 1A disease (CMT1A)
<b>VAILLEND</b>	<b>Cyrille</b>	ORSAY	FRANCE	DECODING CENTRAL DEFECTS IN DYSTROPHINOPATHIES : FROM DIAGNOSTIC TO REMEDIATION

### Pôles stratégiques

<b>LACAMPAGNE</b>	<b>Alain</b>	MONTPELLIER	FRANCE	Pôle Stratégique AFM MYOccitanie : Principales maladies étudiées: Dystrophies musculaires (DMD/BMD/FHSD), titinopathies, syndrome de pseudo-obstruction intestinale chronique (POIC), dyskinésie ciliaire primitive (DCP), mucoviscidose, sarcopénie
<b>MAGDINIER</b>	<b>Frédérique</b>	MARSEILLE	FRANCE	Modélisation and Therapeutic Approaches for Rare Diseases: Principales maladies étudiées: Pathologies liées au gène STIM1 ; Dysferlinopathies ; CMT ; FSHD ; Cardiomyopathies génétiques (LMNA ; Rasopathies...) ; Encephalopathie épileptique KCQN2 ; Syndrome de Rett ; Pathologies du vieillissement (Progeria, progeria like, MADaM syndrome, Hallermann-Streiff syndrome...) ; David syndrome
<b>RELAIX</b>	<b>Frédéric</b>	CRÉTEIL	FRANCE	An integrated translational program for neuromuscular disorders: Principales maladies étudiées: Dystrophies musculaires : DMD ; BMD ; FSHD ; SMA ; Myopathies congénitales ; Myopathies inflammatoires
<b>SCHAEFFER</b>	<b>Laurent</b>	LYON	FRANCE	MyoNeurALP2, The Research Network dedicated to Neuromuscular Disorders in Rhone Alpes Auvergne: Principales maladies étudiées: Dystrophies musculaires : DMD / DM1 ; Myopathies inflammatoires ; Myopathie centronucléaire ; Myopathies congénitales / Myopathie congénitale à « central cores » ; Hyperthermie maligne ; Ataxies, dont Ataxie de Friedreich ; Maladies du motoneurone (SLA / SMA / CMT) ; Myasthénie ; Neuropathies sensorielles

### Structures stratégiques

<b>Association AIDY</b>		PARIS	FRANCE	Aide financière 2026
<b>FONDATION MALADIES RARES</b>		PARIS	FRANCE	Aide financière 2025
<b>GENOPOLE</b>		EVRY-COURCOURONNES	FRANCE	Participation financière de l'AFM-Téléthon au budget 2025 du GIP GENOPOLE

## Outils stratégiques

<b>BASSEZ</b>	<b>Guillaume</b>	PARIS	FRANCE	International Myotonic Dystrophy Registry - iDM-Scope
<b>LAFORET</b>	<b>Pascal</b>	GARCHES	FRANCE	French observatory of patients with type III Glycogenosis
<b>SACCONI</b>	<b>Sabrina</b>	NICE	FRANCE	French national registry for FacioScapuloHumeral muscular Dystrophy (FSHD)

## Plateformes stratégiques

<b>LAFORET</b>	<b>Pascal</b>	GARCHES	FRANCE	Plateformes d'essais thérapeutiques Pédiatriques et Adultes Neuromusculaires - GARCHES
<b>SOLE</b>	<b>Guilhem</b>	BORDEAUX	FRANCE	Plateformes d'essais thérapeutiques Pédiatriques et Adultes Neuromusculaires - BORDEAUX

## AUTRES ACTIONS

### Manifestations scientifiques (congrès, colloques)

<b>BARIS</b>	<b>Olivier</b>	ANGERS	FRANCE	Euromit 2026: International Meeting on Mitochondrial Pathology
<b>BOMONT</b>	<b>Pascale</b>	LYON	FRANCE	European Intermediate Filament meeting 2025
<b>BOYER</b>	<b>Olivier</b>	ROUEN	FRANCE	FOCIS European Advanced Course and Conference on Immunology and Immunopathology, Normandie-France
<b>COLLOQUE JEUNES CHERCHEURS</b>		PARIS	FRANCE	Colloque Jeunes Chercheurs 2025 - Journées Des Familles 2025
<b>CRIST</b>	<b>Colin</b>	MONTREAL	CANADA	Society for Muscle Biology 2025 Frontiers in Myogenesis Conference
<b>DE HAAS</b>	<b>Ria</b>	DEN HAAG	PAYS-BAS	FSHD Connect Europe Meeting
<b>DZIEWCZAPOLSKI</b>	<b>Gustavo</b>	LAKEWOOD	USA	2025 Congenital Muscle Disease Scientific & Family Conference
<b>GARCIA</b>	<b>Pauline</b>	MONTREAL	CANADA	2025 Myogenesis Gordon Research Seminar-Gordon Research Conference "Mechanisms of myogenesis in development, health, and disease"
<b>GOLDBERG</b>	<b>Michael</b>	PITTSBURGH	USA	2025 RYR-1-Related Diseases Patient-Led International Research Workshop: Novel Perspectives, Treatments, & Interventions
<b>HESKAMP</b>	<b>Linda</b>	UTRECHT	PAYS-BAS	Fifth International Imaging in Neuromuscular Disease Conference 2023
<b>HOYAU</b>	<b>Alexandre</b>	SAINT-ALBAN	FRANCE	2nd European CMT Specialist Conference
<b>KINOSHITA</b>	<b>June</b>	RANDOLPH	USA	32nd Annual International Research Congress on FSHD
<b>MICCIO</b>	<b>Annarita</b>	PARIS	FRANCE	CRISPR-Cas: From biology to therapeutic applications
<b>MUCHIR</b>	<b>Antoine</b>	PARIS	FRANCE	5th International Meeting on Laminopathies
<b>RUEGG</b>	<b>Markus</b>	BASEL	SUISSE	International Conference on Muscle Wasting= Molecular Mechanisms of muscle wasting during aging and disease
<b>SMEETS</b>	<b>Hubert J. M.</b>	MAASTRICHT	PAYS-BAS	LAMA2-Muscular Dystrophy: Paving the road to therapy
<b>SORCI</b>	<b>Guglielmo</b>	PERUGIA	ITALIE	22nd IIM International Meeting